Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com

Articles

Adding Patient-Specific Comorbidities May Improve Risk Evaluation in Myelofibrosis

April 11th 2023

Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.

FDA Fast Tracks CB-011 for Relapsed/Refractory Multiple Myeloma

April 6th 2023

The FDA has granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.

Venetoclax Induces Notable ORR But Short PFS in High-Risk Mantle Cell Lymphoma

April 5th 2023

Venetoclax, alone or in combination with a BTK inhibitor, improved overall response rate in patients with pretreated, high-risk mantle cell lymphoma, according to findings from a retrospective study. However, the BCL-2 inhibitor was associated with short durations of progression-free survival.

Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC

April 4th 2023

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.

Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases

March 31st 2023

Frontline cemiplimab plus chemotherapy improved overall survival and progression-free survival compared with investigator’s choice of chemotherapy for patients with PD-L1–positive non–small cell lung cancer that has metastasized to the brain.

Improved Understanding of Genomics Drives Excitement in High-Grade Meningiomas

March 31st 2023

At present, there are no FDA-approved systemic therapies for patients with high-grade meningiomas. However, there has been an increase in research surrounding the disease over the past decade, which is improving the prospect a targeted agent may become for this population.

FDA Lifts Partial Hold on VELA Trial Evaluating BLU-222 in Advanced Solid Tumors

March 29th 2023

Blueprint Medicines announced on March 28, 2023, that the FDA has removed a partial clinical hold on the phase 1/2 VELA trial trial of BLU-222.

FDA Issues Guidelines to Support Applications for Accelerated Approvals

March 28th 2023

The FDA has issued draft guidance to improve applications for accelerated approvals, according to a recently issued news release.

Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer

March 27th 2023

Botensilimab in combination with balstilimab induced durable responses in patients with resistant/refractory ovarian cancer.

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Investigators identified a set of microbiome-based biomarkers that may be used to optimize patient selection or increase personalization of treatment for patients with B-cell lymphoma receiving CAR T-cell therapy.

Isolated Hepatic Perfusion With Melphalan Improves PFS, ORR for Patients With Isolated Uveal Melanoma Liver Metastases

March 24th 2023

A one-time treatment with isolated hepatic perfusion with melphalan improved median progression-free survival compared with best alternative treatment for patients with previously untreated isolated liver metastases from uveal melanoma.

Disadvantaged Neighborhoods, Modifiable Chronic Health Conditions Are Associated With Late Deaths in Survivors of Childhood Cancer

March 22nd 2023

Living in a socioeconomically disadvantaged neighborhood or living with modifiable chronic health conditions were associated with an increased risk for death 5 years of more following diagnosis among survivors of childhood cancer, according to findings from a cohort study.

Investigators Struggle to Understand Causes Behind Growth of Appendix Cancer

March 16th 2023

Investigators are unclear about the factors driving the explosive growth in incidence of appendiceal cancer over the past 2 decades.

It’s the Intensity, Not the Hours, That Makes Fellowship Challenging

March 12th 2023

Kevin Raskin, MD, discusses time management, the importance of taking time off, and teaching fellows how to listen to their inner voice.

Artificial Intelligence, MRI, and Interdisciplinary Collaboration Topics Draw Radiologists, Surgeons to Miami

March 4th 2023

The growth of artificial intelligence allows physicians to see tumors in unprecedented ways.

Abatacept/Ruxolitinib May Reduce Cardiotoxicity Associated With Immune Checkpoint Inhibitors

February 23rd 2023

French investigators evaluated a potential solution to reduce myotoxicity and improve survival for patients with cancer receiving treatment with immune checkpoint inhibitors.

EU Approves Durvalumab/Tremelimumab Combo for Advanced Lung, Liver Cancers

February 22nd 2023

The European Union has approved durvalumab plus tremelimumab-actl for first-line treatment of advanced or unresectable hepatocellular carcinoma and in combination with platinum-based chemotherapy in metastatic non–small cell lung cancer, according to a news release from AstraZeneca.

Vedolizumab Plus Standard Prophylaxis Reduces Rate of Lower GI aGVHD

February 19th 2023

The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.

Bispecific LV20.19 CAR T Cells Induce 92% CR Rate in Relapsed/Refractory Mantle Cell Lymphoma

February 17th 2023

Bispecific CAR T-cell therapy targeting both CD20 and CD19 cells induced a 90-day complete response rate of 92% in patients with relapsed/refractory mantle cell lymphoma.

Phase 3 Trial for Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia to Continue Until OS Event Trigger

February 16th 2023

An independent data monitoring committee has recommended that a phase 3 trial evaluating uproleselan plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia should continue to the planned overall survival event trigger.